Neurobehavioral effects in rats with experimentally induced glioblastoma after treatment with the mTOR-inhibitor rapamycin.


Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
15 02 2021
Historique:
received: 18 09 2020
revised: 26 11 2020
accepted: 01 12 2020
pubmed: 8 12 2020
medline: 25 2 2023
entrez: 7 12 2020
Statut: ppublish

Résumé

Psychiatric symptoms as seen in affective and anxiety disorders frequently appear during glioblastoma (GBM) treatment and disease progression, additionally deteriorate patient's daily life routine. These central comorbidities are difficult to recognize and the causes for these effects are unknown. Since overactivation of mechanistic target of rapamycin (mTOR)- signaling is one key driver in GBM growth, the present study aimed at examining in rats with experimentally induced GBM, neurobehavioral consequences during disease progression and therapy. Male Fisher 344 rats were implanted with syngeneic RG2 tumor cells in the right striatum and treated with the mTOR inhibitor rapamycin (3 mg/kg; once daily, for eight days) before behavioral performance, brain protein expression, and blood samples were analyzed. We could show that treatment with rapamycin diminished GBM tumor growth, confirming mTOR-signaling as one key driver for tumor growth. Importantly, in GBM animals' anxiety-like behavior was observed but only after treatment with rapamycin. These behavioral alterations were moreover accompanied by aberrant glucocorticoid receptor, phosphorylated p70 ribosomal S6 kinase alpha (p-p70s6k), and brain derived neurotrophic factor protein expression in the hippocampus and amygdala in the non-tumor-infiltrated hemisphere of the brain. Despite the beneficial effects on GBM tumor growth, our findings indicate that therapy with rapamycin impaired neurobehavioral functioning. This experimental approach has a high translational value. For one, it emphasizes aberrant mTOR functioning as a central feature mechanistically linking complex brain diseases and behavioral disturbances. For another, it highlights the importance of elaborating the cause of unwanted central effects of immunosuppressive and antiproliferative drugs used in transplantation medicine, immunotherapy, and oncology.

Identifiants

pubmed: 33285202
pii: S0028-3908(20)30492-5
doi: 10.1016/j.neuropharm.2020.108424
pii:
doi:

Substances chimiques

Antibiotics, Antineoplastic 0
mTOR protein, rat EC 2.7.1.1
TOR Serine-Threonine Kinases EC 2.7.11.1
Sirolimus W36ZG6FT64

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108424

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Meike Unteroberdörster (M)

Department of Neurosurgery, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany; Department of Neurosurgery, Charité Universitätsmedizin, 10117, Berlin, Germany.

Arne Herring (A)

Institute of Neuropathology, University Hospital Essen, 45122, Essen, Germany.

Ivo Bendix (I)

Department of Pediatrics I/ Neonatology & Experimental Perinatal Neuroscience, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany.

Laura Lückemann (L)

Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany.

Jasmin Petschulat (J)

Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany.

Ulrich Sure (U)

Department of Neurosurgery, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany.

Kathy Keyvani (K)

Institute of Neuropathology, University Hospital Essen, 45122, Essen, Germany.

Susann Hetze (S)

Department of Neurosurgery, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany.

Manfred Schedlowski (M)

Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany; Department of Clinical Neuroscience, Osher Center for Integrative Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden.

Martin Hadamitzky (M)

Institute of Medical Psychology and Behavioral Immunobiology, University Hospital Essen, University of Duisburg-Essen, 45122, Essen, Germany. Electronic address: martin.hadamitzky@uk-essen.de.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH